BLSM (BlossomHill Therapeutics) Shares Buyback Ratio %: 0.00 (As of Aug. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BLSM BlossomHill Therapeutics Inc BLSM
8 GF Score
Price $16.00
View Full Analysis

What is BlossomHill Therapeutics Shares Buyback Ratio %?

BlossomHill Therapeutics BLSM 8 Shares Buyback Ratio % is 0.00 as of Aug. 10, 2026. GuruFocus rates BLSM with a GF Score™ of 8/100.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. BlossomHill Therapeutics's current shares buyback ratio was 0.00%.

BlossomHill Therapeutics Shares Buyback Ratio % Related Terms

BlossomHill Therapeutics Shares Buyback Ratio % Historical Data

* Premium members only.

The historical data trend for BlossomHill Therapeutics's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BlossomHill Therapeutics Shares Buyback Ratio % Chart

BlossomHill Therapeutics Annual Data
Trend Dec24 Dec25
Shares Buyback Ratio %
0.00 0.00

BlossomHill Therapeutics Semi-Annual Data
Dec24 Dec25
Shares Buyback Ratio % 0.00 0.00
BLSM
8GF Score
BlossomHill Therapeutics Inc BLSM
Shares Buyback Ratio % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BlossomHill Therapeutics Shares Buyback Ratio % Calculation

BlossomHill Therapeutics's Shares Buyback Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2024 ) - Shares Outstanding (EOP) (A: Dec. 2025 )) / Shares Outstanding (EOP) (A: Dec. 2024 )
=(29.081 - 29.081) / 29.081
=0.00%

BlossomHill Therapeutics's Shares Buyback Ratio for the quarter that ended in Dec. 2025 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2024 ) - Shares Outstanding (EOP) (A: Dec. 2025 )) / Shares Outstanding (EOP) (A: Dec. 2024 )
=(29.081 - 29.081) / 29.081
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Shares Buyback Ratio % →
What does a Shares Buyback Ratio % of 0.00 mean?
BlossomHill Therapeutics (BLSM) has a Shares Buyback Ratio % of 0.00 as of Aug. 10, 2026. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on BlossomHill Therapeutics and its competitors.
Is BlossomHill Therapeutics' Shares Buyback Ratio % too high?
BlossomHill Therapeutics' current Shares Buyback Ratio % is 0.00. Overall, BlossomHill Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does BlossomHill Therapeutics' Shares Buyback Ratio % compare to ?
BlossomHill Therapeutics' Shares Buyback Ratio % of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Buyback Ratio % for a Biotechnology company?
A good Shares Buyback Ratio % depends on the Biotechnology industry context. However, Shares Buyback Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Buyback Ratio % mean?
A high Shares Buyback Ratio % can signal that a stock is expensive relative to its fundamentals. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on BlossomHill Therapeutics and its competitors. BlossomHill Therapeutics's current Shares Buyback Ratio % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BlossomHill Therapeutics stock overvalued right now?
BlossomHill Therapeutics (BLSM) has a current Shares Buyback Ratio % of 0.00. The current Shares Buyback Ratio % is 0.00. BlossomHill Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Buyback Ratio % calculated?
Shares Buyback Ratio % is calculated from a company's financial statements. For BlossomHill Therapeutics (BLSM), the current Shares Buyback Ratio % is 0.00 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BlossomHill Therapeutics Business Description

Comparable Companies
Address 10255 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.
8GF Score

Get the complete analysis for BLSM

Shares Buyback Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.00
Price